Literature DB >> 2242520

A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis.

D Waters1, J Lespérance, M Francetich, D Causey, P Théroux, Y K Chiang, G Hudon, L Lemarbre, M Reitman, M Joyal.   

Abstract

To determine whether calcium channel blockers influence the progression of coronary atherosclerosis, 383 patients age 65 years or less with 5-75% stenoses in at least four coronary artery segments were selected at random within 1 month of coronary arteriography to participate in double-blind therapy with a placebo or nicardipine 30 mg three times daily. Coronary events (5 deaths, 22 myocardial infarctions, and 28 unstable anginas) occurred in 28 of 192 nicardipine patients and 23 of 191 placebo patients (p = NS). At 24 months coronary arteriography was repeated in 335 patients. Progression, defined as a 10% or more worsening in diameter stenosis, measured quantitatively, was found in 147 of 1,153 lesions (12.7%) in 168 nicardipine patients and in 170 of 1,170 lesions (14.5%) in 167 placebo patients (p = NS). Ninety-two nicardipine patients (55%) and 95 placebo patients (57%) had progression at one or more sites (p = NS). Regression, that is, an improvement by 10% or more in diameter stenosis, was seen in 140 of 2,323 lesions (6.0%) overall, with no significant intergroup difference. Among the 217 patients with 411 stenoses of 20% or less in the first study, such minimal lesions progressed in only 15 of 99 nicardipine patients compared with 32 of 118 placebo patients (15% versus 27%, p = 0.046). In this subgroup, 16 of 178 minimal lesions in nicardipine patients and 38 of 233 minimal lesions in placebo patients progressed (p = 0.038). By stepwise logistic-regression analysis, baseline systolic blood pressure (p = 0.04) and the change in systolic blood pressure between baseline and 6 months (p = 0.002) correlated with progression of minimal lesions. This suggested blood pressure reduction may account for the beneficial action of nicardipine. These results suggested nicardipine has no effect on advanced coronary atherosclerosis but may retard the progression of minimal lesions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242520     DOI: 10.1161/01.cir.82.6.1940

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  49 in total

1.  Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress.

Authors:  J Lespérance; D Waters
Journal:  Int J Card Imaging       Date:  1992

Review 2.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

3.  Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.

Authors:  Derek E Doran; Daiana Weiss; Yong Zhang; Kathy K Griendling; W Robert Taylor
Journal:  Atherosclerosis       Date:  2007-01-16       Impact factor: 5.162

4.  Nifedipine inhibits accumulation of low density lipoprotein and cholesterol in the aorta of normocholesterolaemic rabbits.

Authors:  P Görög; G V Born
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 5.  Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II).

Authors:  J P Herrman; W R Hermans; J Vos; P W Serruys
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

6.  Clinical and angiographic variables affecting the progression of coronary artery disease as determined by quantitative angiography.

Authors:  A Joseph; J D Talley; A Shih; T Crum; R Vogel; J Kupersmith
Journal:  Int J Card Imaging       Date:  1994-09

Review 7.  Current treatment of patients with hypertension: therapeutic implications of INSIGHT.

Authors:  Stefano Taddei; Lorenzo Ghiadoni; Antonio Salvetti
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Quantitative angiographic follow-up studies on the development of coronary artery disease: which coronary segments should be analyzed? Experience from INTACT.

Authors:  S Jost; J Deckers; W Rafflenbeul; J H Reiber; P Nikutta; B Wiese; H Hecker; P Lippolt; M Riedel; C W Nolte
Journal:  Int J Card Imaging       Date:  1993-03

9.  Progression and regression of coronary artery disease in one year. Quantitative angiographic assessment in patients with stable angina pectoris.

Authors:  J Balkin; M M Zion; D Rosenmann; M Ilan; M Klutstein; A S Abraham
Journal:  Int J Card Imaging       Date:  1993-09

10.  Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study.

Authors:  J A Dens; W J Desmet; P Coussement; I K De Scheerder; K Kostopoulos; P Kerdsinchai; C Supanantaroek; J H Piessens
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.